In the United States, 1–1.3 million people suffer from inflammatory bowel disease13; given the development of new therapeutic strategies for inhibiting chronic inflammation in the gastrointestinal tract, we sought to establish the role of IL-25 in the context of colitis-driven colon cancer. Here, IL25 is linked to malignant colon neoplasm.